Extended Data Fig. 2: Survival analysis according to prior RT-directed treatment status and BTK inhibitor exposure.
From: Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial
Progression-free survival (PFS) in patients with (red) and without (blue) prior RT-directed therapy (A) and patients with (red) and without (blue) prior BTK inhibitor exposure (B).
